Analyses from the Stenting and Aggressive Medical management for prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial showed that good control of vascular risk factors (systolic blood pressure, low-density lipoprotein, and exercise) was associated with fewer vascular events and exercise had the biggest impact on the outcome. We sought to determine the type and duration of exercise performed by SAMMPRIS patients during the trial.
SAMMPRIS aggressive medical management included a telephonic lifestyle modification program, INTERVENT, that was provided free of charge to all subjects during the study. We analyzed self-reported data collected by INTERVENT on the patients’ type and duration of exercise from baseline (n=394) to 3 years (n=132). We calculated the mean duration for each exercise type at each time period and then compared the change in exercise duration from baseline using paired t tests and Wilcoxon signed-rank tests.
Walking was the most common form of exercise at all time points, as measured by both the duration of exercise and the number of patients performing the exercise. The mean duration of walking and other aerobic activities increased significantly from baseline to all other time points.
The type of self-reported exercise performed by SAMMPRIS patients included mostly walking or other aerobic activity and increased significantly during follow-up.
*Department of Neurology, Medical University of South Carolina, Charleston, SC
Departments of †Neurology
¶Radiology, University of Iowa, Iowa City, IA
‡Department of public health, Emory University, Atlanta, GA
§Department of Neurology, Centura Health Physician Group Southwest, Durango, CO
∥INTERVENT International, LLC, Savannah, GA
#Department of Neurosurgery, State University of New York at Stony Brook, Stony Brook, NY
**Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda, MD
Supported by National Institutes of Health (NIH) U01, NS058728.
D.F.: received research/salary support from Siemens, Microvention, Penumbra, and Sequent. Medtronic, Sequent, Codman and Shurtleff, Penumbra, and Microvention provided consulting fees to D.F. He received Codman & Shurtleff (REVIVE) royalties and fund from Vascular Simulations LLC. T.N.T.: received personal fees from Gore and Boehringer Ingelheim for participating as a stroke adjudicator in clinical trials unrelated to this work. M.I.C.: received other support from Astra Zeneca and Stryker Neurovascular (formerly Boston Scientific Neurovascular) related to the Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. N.G.: is a member of INTERVENT international LLC. The remaining authors declare no conflict of interest.
Correspondence to: Sami Al Kasab, MD, Department of Neurology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa city, IA 52242. E-mail: email@example.com.